Republic of Korea-based biosimilar developer Celltrion announced on December 16 that it has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for its trastuzumab biosimilar, referenced on Roche’s blockbuster anticancer therapy, Herceptin. The positive opinion will now be referred to the European Commission for final review.
Republic of Korea-based biosimilar developer Celltrion announced on December 16 that it has received a positive opinion from the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) for its trastuzumab biosimilar, referenced on Roche’s blockbuster anticancer therapy, Herceptin. The positive opinion will now be referred to the European Commission (EC) for final review.
CHMP recommended that the product, which Celltrion hopes to market in the European Union (EU) as Herzuma, be granted marketing authorization for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification.
“We welcome the CHMP’s recommendation. By providing more treatment options, biosimilars open more opportunities for greater affordability and improve access to wider use of biotherapeutics,” Woo Sung Kee, CEO of Celltrion, said in a statement. “Herzuma could become a cost-effective alternative to biologics for treatment of breast cancer and gastric cancer, since biologics, which cost much more than conventional anticancer drugs, place undue financial burden on patients and the general healthcare system,” he added.
A representative from Celltrion Healthcare, Celltrion’s marketing arm, recently told The Investor that Herzuma could be launched in Europe as early as 3 months following its final approval by the EC. On the strength of the positive opinion, coupled with positive forecasts for Celltrion’s biosimilar infliximab (marketed in the EU as Remsima and in the United States as Inflectra) and rituximab (Truxima), some analysts say that the growing Celltrion could see its annual revenue exceed $2.7 billion by 2022.
However, Herzuma will face EU competition from other biosimilar challengers to the reference Herceptin. Samsung Bioepis’ trastuzumab biosimilar, Ontruzant, gained a positive opinion from CHMP in September 2017 and is also awaiting the EC’s final clearance. Mylan—Biocon’s Ogivri, for which the biosimilar development partnership recently resubmitted a previously withdrawn EMA marketing application, was recently approved by the FDA as the first US trastuzumab biosimilar.
Celltrion also filed a Biologics License Application (BLA) for its trastuzumab with the FDA in July 2017. The BLA includes efficacy, safety, immunogenicity, pharmacodynamic, and pharmacokinetic data from trials conducted in over 500 patients in 22 countries, and comprises data from a phase 3 equivalence trial of the proposed biosimilar as neoadjuvant treatment in HER2-positive early breast cancer. Celltrion has not disclosed a biosimilar user fee act date for this BLA.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.